Gedeon Richter PLC (BUD:RICHTER)
Hungary · Delayed Price · Currency is HUF | Market Cap | 2.25T +16.5% |
| Revenue (ttm) | 925.05B +2.4% |
| Net Income | 215.91B -2.3% |
| EPS | 1,180.33 -2.3% |
| Shares Out | 182.39M |
| PE Ratio | 10.46 |
| Forward PE | 8.11 |
| Dividend | 508.00 (4.11%) |
| Ex-Dividend Date | Jun 3, 2026 |
| Volume | 166,760 |
| Open | 12,350 |
| Previous Close | 12,350 |
| Day's Range | 12,280 - 12,440 |
| 52-Week Range | 9,380 - 13,570 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 13,214.57 (+7.0%) |
| Earnings Date | Nov 10, 2026 |
About Gedeon Richter
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as we... [Read more]
Financial Performance
In 2025, Gedeon Richter's revenue was 928.96 billion, an increase of 8.33% compared to the previous year's 857.55 billion. Earnings were 232.34 billion, a decrease of -2.89%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for RICHTER stock is "Buy." The 12-month stock price target is Ft 13,215, which is an increase of 7.00% from the latest price.
News
Gedeon Richter Earnings Call Transcript: Q2 2026
Q2 2026 saw strong underlying growth, especially in CNS and biotech, despite FX headwinds. Clean EBIT guidance was upgraded to double-digit growth, with record free cash flow and continued benefits from restructuring. GenMed recovery is expected next year, and capital allocation remains focused on dividends and M&A.
Gedeon Richter Quarterly report: Q2 2026
Gedeon Richter has published its Q2 2026 quarterly earnings report on August 7, 2026.
Gedeon Richter Slides: Q2 2026
Gedeon Richter has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Gedeon Richter Earnings release: Q2 2026
Gedeon Richter released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Gedeon Richter Slides: Investor presentation
Gedeon Richter has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Gedeon Richter Earnings Call Transcript: Q1 2026
Q1 2026 saw strong growth in CNS and BioTech, offset by headwinds in General Medicines and Women's Healthcare due to timing and regulatory factors. Clean EBIT grew 15% at constant FX, but reported growth was 1.5% due to currency headwinds. High single-digit growth guidance is reiterated for 2026.
Gedeon Richter Slides: Q1 2026
Gedeon Richter has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Gedeon Richter Earnings release: Q1 2026
Gedeon Richter released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Gedeon Richter Slides: Investor presentation
Gedeon Richter has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Gedeon Richter Earnings Call Transcript: Q4 2025
2025 ended with strong revenue and profit growth, led by Women's Health and innovative products, despite FX and tax headwinds. Outlook for 2026 is high single-digit growth, with continued investment in R&D and efficiency, and new product launches expected to drive future gains.
Gedeon Richter Annual report: Q4 2025
Gedeon Richter has published its Q4 2025 annual report on February 26, 2026.
Gedeon Richter Slides: Q4 2025
Gedeon Richter has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Gedeon Richter Slides: Investor presentation
Gedeon Richter has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Gedeon Richter Earnings Call Transcript: Q3 2025
Q3 2025 saw strong growth in innovative segments but was offset by headwinds in GenMed and CDMO, leading to a temporary revenue slowdown. Free cash flow hit a record high, and full-year Clean EBIT is projected to grow 8%-10%. Gross margin is expected to improve in Q4.
Gedeon Richter Slides: Q3 2025
Gedeon Richter has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Gedeon Richter Earnings Call Transcript: Q2 2025
Pharma sales grew 10.7% YoY in H1 2025, with clean EBIT up 15% and Women's Health leading segment growth. FX volatility and inventory write-offs impacted cash flow, but guidance for 10% revenue and EBIT growth remains on track.
Gedeon Richter Quarterly report: Q2 2025
Gedeon Richter has published its Q2 2025 quarterly earnings report on August 6, 2025.
Gedeon Richter Slides: Q2 2025
Gedeon Richter has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 6, 2025.
Gedeon Richter price target lowered to HUF 12,400 at RBC Capital
RBC Capital lowered the firm’s price target on Gedeon Richter (RGEDF) to HUF 12,400 from HUF 12,500 and keeps an Outperform rating on the shares.
Gedeon Richter Earnings Call Transcript: Q1 2025
Q1 2025 saw strong revenue and EBIT growth, record free cash flow, and robust performance in general medicines and biosimilars. Four biosimilar launches are planned within 12 months, and the company maintains a solid cash position to support dividends and R&D.
Gedeon Richter Slides: Q1 2025
Gedeon Richter has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on May 13, 2025.
Gedeon Richter Slides: Investor Presentation
Gedeon Richter has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2025.
Gedeon Richter upgraded to Buy from Hold at HSBC
HSBC analyst Raj Sinha upgraded Gedeon Richter (RGEDF) to Buy from Hold with a price target of HUF 11,700, up from HUF 11,000. The firm says the company’s long-term targets…
Gedeon Richter price target raised to HUF 12,390 from HUF 12,000 at Berenberg
Berenberg raised the firm’s price target on Gedeon Richter (RGEDF) to HUF 12,390 from HUF 12,000 and keeps a Buy rating on the shares.
Gedeon Richter Slides: FY 2025
Gedeon Richter has posted slides in relation to its FY 2025 quarterly earnings report, which was published on March 5, 2025.